Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy

NCT00307294 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00307294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00307294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
January 31, 2012
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer